Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Major depressive disorder (MDD), also referred to as depression, is a severe medical illness that disrupts a person’s mood, behavior, thought processes, and physical health. Sadness and grief are normal reactions to life stresses. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme “high” feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The decline in hippocampal function, which is believed to have an inhibitory effect on the hypothalamic-pituitary-adrenal (HPA) axis, could potentially be responsible for the hypercortisolemia seen in depression. Pro-inflammatory marker levels are reported to be elevated in depressed patients, such as C-reactive protein (CRP), interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α).
·
According to research, the prevalence of major
depressive disorder (MDD) differs significantly across geographies, including
the US (7.1%, 16.2 M) and Japan (4.7%, 5.0 M). In the US, MDD sufferers were
more likely to be women than non-sufferers and were significantly younger
(ps<0.05).
Thelansis’s “Major Depressive Disorder
(MDD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Major
Depressive Disorder (MDD) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Major Depressive Disorder (MDD) across the 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Major Depressive Disorder (MDD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment